Kami Maddocks, MD
Kami Maddocks, MD
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, MALT lymphoma, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, nodal marginal zone B-cell lymphoma, plasma cell neoplasm, splenic marginal zone lymphoma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-07-22 | NCT01479842 | |
| PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm, prolymphocytic leukemia | Active, not recruiting | Phase 2 | 2026-04-13 | NCT01589302 |